

S J Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1863332/publications.pdf>

Version: 2024-02-01

220
papers

5,796
citations

101384

36
h-index

123241

61
g-index

224
all docs

224
docs citations

224
times ranked

8672
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 1383-1391.e6.	0.6	371
2	A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 7-17.	4.5	232
3	An endoscope with integrated transparent bioelectronics and theranostic nanoparticles for colon cancer treatment. <i>Nature Communications</i> , 2015, 6, 10059.	5.8	159
4	Long-term Prognosis of Combined Hepatocellular and Cholangiocarcinoma After Curative Resection Comparison With Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 69-75.	1.1	130
5	Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. <i>Nature Communications</i> , 2017, 8, 839.	5.8	107
6	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 1093-1102.	1.8	107
7	A genome-wide association study identified new variants associated with the risk of chronic hepatitis B. <i>Human Molecular Genetics</i> , 2013, 22, 4233-4238.	1.4	105
8	Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. <i>Annals of Surgery</i> , 2016, 263, 842-850.	2.1	105
9	Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique. <i>European Radiology</i> , 2019, 29, 6499-6507.	2.3	104
10	Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 347-354.	1.8	103
11	Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 449-457.	1.8	102
12	Small Single-Nodule Hepatocellular Carcinoma: Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. <i>Radiology</i> , 2014, 271, 909-918.	3.6	97
13	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1305-1315.	2.0	93
14	Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. <i>Hepatology</i> , 2017, 66, 1556-1569.	3.6	92
15	High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. <i>Hepatology</i> , 2015, 61, 1261-1268.	3.6	90
16	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. <i>Cell Death and Disease</i> , 2018, 9, 620.	2.7	90
17	Accuracy of Two-Dimensional Shear Wave Elastography and Attenuation Imaging for Evaluation of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 797-805.e7.	2.4	86
18	Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e2159.	0.4	85

#	ARTICLE	IF	CITATIONS
19	Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 259-264.	1.3	78
20	Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 845-855.	1.9	73
21	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: Risk of HCC recurrence after radiofrequency ablation. <i>Journal of Hepatology</i> , 2015, 62, 1122-1130.	1.8	70
22	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 23-32.	2.0	62
23	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
24	<scp>CLIF</scp>â€<scp>SOFA</scp> scoring system accurately predicts shortâ€term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis. <i>Liver International</i> , 2015, 35, 46-57.	1.9	55
25	High titers of antiâ€HBs prevent rituximabâ€related viral reactivation in resolved hepatitis B patient with nonâ€Hodgkin's lymphoma. <i>Journal of Medical Virology</i> , 2016, 88, 1010-1017.	2.5	50
26	Hepatitis B viral load affects prognosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 12039.	1.4	50
27	Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2010, 298, 9-15.	3.2	49
28	Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications. <i>Thrombosis Research</i> , 2018, 163, 71-76.	0.8	47
29	Steatohepatitis Impairs T-cellâ€Directed Immunotherapies Against Liver Tumors in Mice. <i>Gastroenterology</i> , 2021, 160, 331-345.e6.	0.6	46
30	Association of Metabolic Risk Factors With Risks of Cancer and Allâ€Cause Mortality in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021, 73, 2266-2277.	3.6	45
31	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 567-572.	1.2	44
32	Does 18F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?. <i>PLoS ONE</i> , 2014, 9, e105679.	1.1	43
33	Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0144526.	1.1	43
34	A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. <i>Liver Cancer</i> , 2020, 9, 503-517.	4.2	40
35	Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. <i>Journal of Bioenergetics and Biomembranes</i> , 2012, 44, 101-115.	1.0	39
36	Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. <i>PLoS ONE</i> , 2016, 11, e0160822.	1.1	38

#	ARTICLE	IF	CITATIONS
37	Tauroursodeoxycholic Acid Attenuates Progression of Steatohepatitis in Mice Fed a Methionine- ⁶ Choline-Deficient Diet. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1461-1474.	1.1	37
38	Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. <i>World Journal of Hepatology</i> , 2015, 7, 1553.	0.8	37
39	Serum fibronectin distinguishes the early stages of hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 9449.	1.6	37
40	Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 544-553.	5.7	36
41	Clinical Assay for AFP-L3 by Using Multiple Reaction Monitoring- ⁶ Mass Spectrometry for Diagnosing Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2018, 64, 1230-1238.	1.5	36
42	Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 912-920.	2.8	35
43	Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. <i>Hepatology</i> , 2017, 66, 855-868.	3.6	35
44	Association of the Frequency and Quantity of Alcohol Consumption With Gastrointestinal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2120382.	2.8	35
45	Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding. <i>Gut and Liver</i> , 2018, 12, 704-713.	1.4	34
46	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen- ⁶ Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 1407-1414.	1.9	33
47	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. <i>PLoS ONE</i> , 2016, 11, e0165722.	1.1	33
48	Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 529-539.	4.5	33
49	Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 635-643.	1.2	32
50	Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6710-6716.	1.4	32
51	Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 651-659.	0.2	32
52	Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1292.	1.8	32
53	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 328-339.	4.5	32
54	Risk Factors, Clinical Features, and Prognosis of the Hepatocellular Carcinoma with Peritoneal Metastasis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 813-819.	1.1	31

#	ARTICLE	IF	CITATIONS
55	Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. <i>European Radiology</i> , 2017, 27, 1448-1458.	2.3	31
56	Development of Biomarkers for Screening Hepatocellular Carcinoma Using Global Data Mining and Multiple Reaction Monitoring. <i>PLoS ONE</i> , 2013, 8, e63468.	1.1	30
57	Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 607-616.	2.5	30
58	Hepatocellular Carcinoma: High Hepatitis B Viral Load and Mortality in Patients Treated with Transarterial Chemoembolization. <i>Radiology</i> , 2013, 267, 638-647.	3.6	28
59	Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. <i>Clinical Cancer Research</i> , 2013, 19, 4218-4227.	3.2	28
60	Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1730-1737.	1.4	28
61	Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. <i>Cancer Letters</i> , 2008, 271, 314-322.	3.2	27
62	Polymorphisms near Interleukin 28B Gene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence. <i>Intervirology</i> , 2013, 56, 84-90.	1.2	27
63	Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. <i>Journal of Proteome Research</i> , 2017, 16, 1239-1248.	1.8	27
64	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	3.2	27
65	Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. <i>Hepatology</i> , 2022, 76, 492-501.	3.6	26
66	Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1312-1323.	2.5	25
67	Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 873-881.	1.0	24
68	Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. <i>Liver International</i> , 2015, 35, 2530-2536.	1.9	24
69	17 β -estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 1247-1254.	1.0	24
70	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. <i>European Radiology</i> , 2018, 28, 3513-3521.	2.3	24
71	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. <i>BMC Cancer</i> , 2019, 19, 523.	1.1	24
72	Additional fibrate treatment in UDCA-refractory PBC patients. <i>Liver International</i> , 2019, 39, 1776-1785.	1.9	24

#	ARTICLE	IF	CITATIONS
73	Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 400-404.	0.6	23
74	Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 65-75.	4.2	23
75	Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 707-717.	1.0	23
76	Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance. <i>Cancers</i> , 2020, 12, 1805.	1.7	23
77	Liver enzyme variability and risk of heart disease and mortality: A nationwide population-based study. <i>Liver International</i> , 2020, 40, 1292-1302.	1.9	23
78	Association of Polymorphism in Pri-microRNAs-371-372-373 with the Occurrence of Hepatocellular Carcinoma in Hepatitis B Virus Infected Patients. <i>PLoS ONE</i> , 2012, 7, e41983.	1.1	23
79	Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2568-2577.	1.1	22
80	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1490-1501.	1.9	22
81	Association of <i>VARS</i> and <i>SFTA</i> polymorphisms with the risk of chronic hepatitis B in a Korean population. <i>Liver International</i> , 2015, 35, 1934-1940.	1.9	21
82	Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence. <i>Journal of Korean Medical Science</i> , 2018, 33, e283.	1.1	21
83	Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. <i>Endocrine-Related Cancer</i> , 2014, 21, 343-353.	1.6	20
84	High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 444-449.	1.1	20
85	Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 972-978.	1.4	20
86	Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 633-641.	1.1	20
87	Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study. <i>Radiology</i> , 2021, 301, 625-634.	3.6	20
88	Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation. <i>Liver International</i> , 2013, 33, 884-893.	1.9	19
89	Prevalence of upper gastrointestinal bleeding risk factors among the general population and osteoarthritis patients. <i>World Journal of Gastroenterology</i> , 2016, 22, 10643.	1.4	19
90	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016, 115, 1201-1205.	2.9	19

#	ARTICLE	IF	CITATIONS
91	Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154866.	1.5	19
92	Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. <i>Liver Cancer</i> , 2021, 10, 72-81.	4.2	19
93	STAT3 & Cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 612-616.	2.5	18
94	Spontaneous Evolution in Bilirubin Levels Predicts Liver-Related Mortality in Patients with Alcoholic Hepatitis. <i>PLoS ONE</i> , 2014, 9, e100870.	1.1	18
95	3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells. <i>PLoS ONE</i> , 2017, 12, e0174271.	1.1	18
96	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. <i>BMC Cancer</i> , 2018, 18, 307.	1.1	18
97	Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1161-1171.	1.0	18
98	No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study. <i>Korean Journal of Radiology</i> , 2021, 22, 1974.	1.5	18
99	Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. <i>Oncology Reports</i> , 2011, 25, 1739-46.	1.2	17
100	Association of a microRNA-323b polymorphism with the persistence of hepatitis B virus infection by the enhancement of viral replication. <i>Journal of Viral Hepatitis</i> , 2014, 21, 853-859.	1.0	17
101	Role of C-Arm CT in Identifying Caudate Arteries Supplying Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1380-1388.	0.2	17
102	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. <i>European Radiology</i> , 2019, 29, 3122-3131.	2.3	17
103	A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. <i>BMC Cancer</i> , 2020, 20, 504.	1.1	17
104	Comparison of the Effects of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma between Patients with and without Extrahepatic Metastases. <i>PLoS ONE</i> , 2014, 9, e113926.	1.1	17
105	Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy. <i>Gut and Liver</i> , 2020, 14, 755-764.	1.4	17
106	Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclearance: a systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2014, 21, 163-170.	1.0	16
107	Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2037-2045.	1.2	16
108	Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo mice. <i>European Journal of Pharmacology</i> , 2015, 762, 247-255.	1.7	16

#	ARTICLE	IF	CITATIONS
109	Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio. <i>Gut and Liver</i> , 2018, 12, 714-721.	1.4	16
110	A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 580.	0.7	16
111	Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1859-1868.	1.4	15
112	Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2015, 35, 1992-2000.	1.9	15
113	Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 286-291.	4.5	15
114	Bleeding complications in critically ill patients with liver cirrhosis. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 288-295.	0.7	15
115	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. <i>Cancer Research and Treatment</i> , 2018, 50, 366-373.	1.3	15
116	Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 465-472.	2.2	15
117	Anti-apoptotic N-cadherin signaling and its prognostic implication in human hepatocellular carcinomas. <i>Oncology Reports</i> , 2006, 15, 1117-23.	1.2	15
118	Paper Alert. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1295-1298.	0.8	14
119	Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. <i>PLoS ONE</i> , 2016, 11, e0161980.	1.1	14
120	Timing of upper gastrointestinal endoscopy does not influence short-term outcomes in patients with acute variceal bleeding. <i>World Journal of Gastroenterology</i> , 2018, 24, 5025-5033.	1.4	14
121	Predictors of HBsAg Seroclearance in HBsAg-Negative Chronic Hepatitis B Patients. <i>Digestion</i> , 2011, 84, 23-28.	1.2	13
122	Efficacy of Adefovir-Based Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6325-6332.	1.4	13
123	Measurement of Glycosylated Alpha-Fetoprotein Improves Diagnostic Power over the Native Form in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e110366.	1.1	13
124	Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm. <i>Medicine (United States)</i> , 2016, 95, e4551.	0.4	13
125	Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model. <i>Cancer Biology and Therapy</i> , 2017, 18, 67-75.	1.5	13
126	Identification of novel <i>OCT4</i> genetic variant associated with the risk of chronic hepatitis B in a Korean population. <i>Liver International</i> , 2017, 37, 354-361.	1.9	13

#	ARTICLE	IF	CITATIONS
127	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 66-73.	4.5	13
128	Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, e18-e26.	1.1	13
129	Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. <i>Genes and Immunity</i> , 2019, 20, 1-9.	2.2	13
130	Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1960-1968.	1.4	13
131	Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 133-144.	1.2	12
132	The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. <i>Korean Journal of Radiology</i> , 2015, 16, 1283.	1.5	12
133	Cone Beam CT-Guided Chemoembolization of Probable Hepatocellular Carcinomas Smaller than 1 cm in Patients at High Risk of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 795-803.e1.	0.2	12
134	Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study. <i>Korean Journal of Radiology</i> , 2017, 18, 799.	1.5	12
135	Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. <i>International Journal of Molecular Medicine</i> , 2018, 42, 2551-2559.	1.8	12
136	The Clinicopathological and Prognostic Significance of Nrf2 and Keap1 Expression in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2128.	1.7	12
137	Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study. <i>Clinical Infectious Diseases</i> , 2020, 73, e3308-e3316.	2.9	12
138	Two-Dimensional-Shear Wave Elastography with a Propagation Map: Prospective Evaluation of Liver Fibrosis Using Histopathology as the Reference Standard. <i>Korean Journal of Radiology</i> , 2020, 21, 1317.	1.5	12
139	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 358.	4.5	12
140	Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1565-1577.	1.8	12
141	Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2010, 295, 229-235.	3.2	11
142	TGFBR3 Polymorphisms and Its Haplotypes Associated with Chronic Hepatitis B Virus Infection and Age of Hepatocellular Carcinoma Occurrence. <i>Digestive Diseases</i> , 2011, 29, 278-283.	0.8	11
143	Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area. <i>PLoS ONE</i> , 2017, 12, e0170394.	1.1	11
144	Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBsAg-positive high viral load chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2018, 25, 552-560.	1.0	11

#	ARTICLE	IF	CITATIONS
145	Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. <i>Cancers</i> , 2019, 11, 1295.	1.7	11
146	Glucose Variability and Risk of Hepatocellular Carcinoma in Patients with Diabetes: A Nationwide Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 974-981.	1.1	11
147	Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization. <i>PLoS ONE</i> , 2014, 9, e90862.	1.1	11
148	Validation of P2/MS and Other Noninvasive Fibrosis Scoring Systems in the Korean Population with Nonalcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2011, 57, 19.	0.2	10
149	Topographical Impact of Hepatitis B-related Hepatocellular Carcinoma on Local Recurrence After Radiofrequency Ablation. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 66-72.	1.1	10
150	Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis. <i>British Journal of Radiology</i> , 2016, 89, 20160383.	1.0	10
151	Anakinra Protects Against Serum Deprivation-Induced Inflammation and Functional Derangement in Islets Isolated From Nonhuman Primates. <i>American Journal of Transplantation</i> , 2017, 17, 365-376.	2.6	10
152	Timely diagnosis of pulmonary artery tumor embolism by ultrasound-guided transbronchial needle aspiration. <i>Thoracic Cancer</i> , 2014, 5, 184-187.	0.8	9
153	A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 2829-2838.	1.9	9
154	Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 156, 142-146.	1.4	9
155	Hepatitis B virus X protein induces size-selective membrane permeabilization through interaction with cardiolipin. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2019, 1861, 729-737.	1.4	9
156	Quantitative Assessment of Fatty Liver using Ultrasound with Normalized Local Variance Technique. <i>Ultraschall in Der Medizin</i> , 2021, 42, 599-606.	0.8	9
157	Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 613-623.	1.8	9
158	Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 6009.	1.7	9
159	Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2017, 12, e0166188.	1.1	8
160	Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 261-268.	0.7	8
161	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. <i>Cancers</i> , 2019, 11, 1721.	1.7	8
162	Epidemiological and Clinical History of Viral Hepatitis in Korea. <i>Infection and Chemotherapy</i> , 2021, 53, 159.	1.0	8

#	ARTICLE	IF	CITATIONS
163	Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode. <i>Korean Journal of Radiology</i> , 2021, 22, 179.	1.5	8
164	Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2015, 10, e0130392.	1.1	8
165	Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. <i>PLoS ONE</i> , 2020, 15, e0239733.	1.1	8
166	Repeated Intra-Arterial Therapy via the Cystic Artery for Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 1283-1291.	0.9	7
167	Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. <i>Scientific Reports</i> , 2018, 8, 13651.	1.6	7
168	Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model. <i>Journal of Bioenergetics and Biomembranes</i> , 2019, 51, 121-129.	1.0	7
169	Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. <i>Gut and Liver</i> , 2021, 15, 410-419.	1.4	7
170	Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. <i>Liver International</i> , 2022, 42, 320-329.	1.9	7
171	Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Diagnostics</i> , 2022, 12, 1170.	1.3	7
172	The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1363-1370.	1.1	6
173	Reduction of Oxidative Stress Attenuates Lipoapoptosis Exacerbated by Hypoxia in Human Hepatocytes. <i>International Journal of Molecular Sciences</i> , 2015, 16, 3323-3334.	1.8	6
174	Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. <i>Journal of Medical Virology</i> , 2018, 90, 1593-1603.	2.5	6
175	Favorable impact of non-alcoholic fatty liver disease on the cerebral white matter hyperintensity in a neurologically healthy population. <i>European Journal of Neurology</i> , 2019, 26, 1471-1478.	1.7	6
176	Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study. <i>Hepatology International</i> , 2021, 15, 482-492.	1.9	6
177	Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification. <i>Gut and Liver</i> , 2018, 12, 571-582.	1.4	6
178	Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults. <i>Journal of Clinical Medicine</i> , 2022, 11, 935.	1.0	6
179	A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. <i>Digestive and Liver Disease</i> , 2017, 49, 1273-1279.	0.4	5
180	Mesalamine-induced B7-1 expression on hepatic stellate cells attenuates autoimmune liver injury. <i>Hepatology Research</i> , 2011, 41, 79-86.	1.8	4

#	ARTICLE	IF	CITATIONS
181	Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 243-250.	1.1	4
182	Side population in <sc>LX2</sc> cells decreased by transforming growth factor α . <i>Hepatology Research</i> , 2014, 44, 229-237.	1.8	4
183	JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. <i>Molecular Medicine Reports</i> , 2015, 11, 263-268.	1.1	4
184	Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause of Proteinuria in Korean Patients with Chronic Hepatitis B. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	0.7	4
185	Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. <i>Journal of Bioenergetics and Biomembranes</i> , 2016, 48, 581-590.	1.0	4
186	CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 1001.	1.1	4
187	Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. <i>Cancer Gene Therapy</i> , 2021, , .	2.2	4
188	Concurrent transarterial radioembolization and combination atezolizumab/ bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report. <i>Journal of Liver Cancer</i> , 2022, 22, 69-74.	0.3	4
189	Prognosis of surgical hernia repair in cirrhotic patients with refractory ascites. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2020, 24, 481-488.	0.9	3
190	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	1.1	3
191	Comparative study on proliferation activity in small hepatocellular carcinoma related to hepatitis virus B and C. <i>World Journal of Gastroenterology</i> , 1997, 3, 236.	1.4	3
192	Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2020, 20, 1-16.	0.3	3
193	Regression of liver cirrhosis: Orthodoxy or paradigm shift?. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 22.	4.5	2
194	Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2010, 16, 389.	1.5	2
195	Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2020, 14, 225-231.	1.4	2
196	Anticoagulation Treatment with Low Molecular-Weight Heparin for Portal Vein Thrombosis in Liver Cirrhosis: Efficacy and Risk of Hemorrhagic Complications. <i>Blood</i> , 2016, 128, 1435-1435.	0.6	2
197	Lack of association between serum leptin levels and hepatic steatosis, fibrosis or response to antiviral therapy in Korean chronic hepatitis C patients. <i>Hepato-Gastroenterology</i> , 2007, 54, 844-8.	0.5	2
198	Low P2/MS value is an independent risk factor for early recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. <i>Hepato-Gastroenterology</i> , 2011, 58, 147-52.	0.5	2

#	ARTICLE	IF	CITATIONS
199	Molecular targeted therapy with transarterial chemoembolization. <i>Gastrointestinal Intervention</i> , 2013, 2, 78-81.	0.1	1
200	A Model for Adaptive Decision Making of “Ablate-and-Wait” Versus Transplantation in Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 655-661.	1.1	1
201	Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-9.	0.7	1
202	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 587-598.	1.8	1
203	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	1.4	1
204	Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. <i>Oncotarget</i> , 2017, 8, 47555-47564.	0.8	1
205	Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Journal of Liver Cancer</i> , 2019, 19, 128-135.	0.3	1
206	Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. <i>Gut and Liver</i> , 2020, 14, 377-386.	1.4	1
207	Disparities in Liver Cancer Surveillance Among People With Disabilities. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 439-448.	1.1	1
208	Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. <i>Journal of Medical Virology</i> , 2015, 87, 999-1007.	2.5	0
209	The association between microRNA-323b polymorphism and hepatitis B virus persistent infection “some problems should be addressed. <i>Journal of Viral Hepatitis</i> , 2015, 22, 626-626.	1.0	0
210	Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3767-3774.	2.0	0
211	Analysis of significant protein abundance from multiple reaction-monitoring data. <i>BMC Systems Biology</i> , 2018, 12, 123.	3.0	0
212	SAT-224-Design and validation of a risk prediction model for hepatocellular carcinoma development after sustained virological response in chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2019, 70, e728.	1.8	0
213	FRI-035-Clinical outcomes associated with additional fibrate treatment in UDCA-refractory PBC patients: A multicenter study. <i>Journal of Hepatology</i> , 2019, 70, e399-e400.	1.8	0
214	The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 370-377.	1.1	0
215	Direct-acting antivirals improve treatment outcomes in patients with chronic hepatitis C-related hepatocellular carcinoma treated with transarterial chemoembolization: a nationwide, multi-center, retrospective cohort study. <i>Journal of Hepatology</i> , 2020, 73, S612-S613.	1.8	0
216	Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure. <i>Journal of Hepatology</i> , 2020, 73, S913-S914.	1.8	0

#	ARTICLE	IF	CITATIONS
217	Empirical carbapenem versus third-generation cephalosporin treatment for spontaneous bacterial peritonitis: a multicenter study. <i>Journal of Hepatology</i> , 2020, 73, S769-S770.	1.8	0
218	Comparison of the risk of hepatocellular carcinoma in nucleos(t) ide analogue-naive chronic hepatitis B patients treated with entecavir versus tenofovir : a systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020, 73, S582-S583.	1.8	0
219	A Case of Acrometastasis in the Right First Metatarsal Bone Caused by a Metastatic Hepatocellular Carcinoma. <i>Korean Journal of Medicine</i> , 2013, 84, 81.	0.1	0
220	Hepatocellular Carcinoma with Segmental Portal Vein Invasion Exhibiting a Complete Response after Transarterial Radioembolization. <i>Journal of Liver Cancer</i> , 2019, 19, 159-164.	0.3	0